Advanced Contract Award Notice - Smallpox antiviral
An ACAN is a public notice indicating to the supplier community that a department or agency intends to award a contract for goods, services or construction to a pre-identified supplier, thereby allowing other suppliers to signal their interest in bidding, by submitting a statement of capabilities. If no supplier submits a statement of capabilities that meets the requirements set out in the ACAN, on or before the closing date stated in the ACAN, the contracting officer may then proceed with the award to the pre identified supplier.
Purpose of this ACAN:
Public Services and Procurement Canada proposes to negotiate a contract with Emergent Biodefense Operations Lansing LLC. on behalf of the Public Health Agency of Canada (PHAC) for the purchase of Tembexa® (brincidofovir) which is an antiviral used to treat smallpox.
Limited Tendering Reason:
In accordance with Government Contract Regulations (GCRs Part 1 - Conditions of Contract Entry - Bids - 6.(d)) Emergent Biodefense Operations Lansing LLC., is the only known supplier capable of providing an antiviral that is a nucleotide analog DNA polymerase inhibitor and also for treatment of smallpox in pediatric patients.
